{"id":23898,"date":"2019-10-01T12:30:41","date_gmt":"2019-10-01T10:30:41","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&#038;p=23898"},"modified":"2026-09-04T16:10:34","modified_gmt":"2026-09-04T14:10:34","slug":"veeva-2019-unified-clinical-operations-survey-report","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/","title":{"rendered":"Veeva 2019 Unified Clinical Operations Survey Report"},"content":{"rendered":"<p>\nThe <em>Veeva 2019 Unified Clinical Operations Survey Report<\/em> examines the life sciences<br \/>\nindustry\u2019s progress toward a unified clinical operating environment by gathering the<br \/>\nexperiences and opinions of 461 clinical operations professionals from around the<br \/>\nglobe. The annual research details the drivers, barriers, and benefits of a unified<br \/>\nclinical operating model and tracks the industry\u2019s progress in its move to unify clinical<br \/>\nsystems and processes and align stakeholders throughout study execution.\n<\/p>\n<h2>Executive Summary<\/h2>\n<p>\nFindings show the industry is making progress in unifying clinical systems, streamlining end-to-end<br \/>\nprocesses, and aligning stakeholders to improve trial performance.\n<\/p>\n<ul>\n<li>Standalone, eClinical applications, including EDC (88%), eTMF (69%), and CTMS (61%) are now<br \/>\nutilized by the majority of sponsors and CROs as they steadily adopt function-specific technologies to<br \/>\nsupport clinical trials.<\/li>\n<li>Nearly all (99%) respondents report the need to unify clinical applications to achieve better visibility<br \/>\nand oversight (70%), faster trials (63%), and easier stakeholder collaboration (61%).<\/li>\n<li>Consistent with the aim to improve collaboration, all respondents say they want to improve methods of<br \/>\ninformation exchange between sponsors, CROs, and sites. Primary reasons include reduced manual<br \/>\nprocesses (71%), improved collaboration (66%), and better visibility and oversight (64%).<\/li>\n<li>All respondents report significant challenges with study start-up, likely due to the heavy reliance on<br \/>\nmanual processes since most (81%) use spreadsheets to manage this area.<\/li>\n<li>Sponsors and CROs have made progress modernizing major clinical areas such as eTMF to ensure a<br \/>\nconstant state of inspection readiness (60%) and increase visibility into TMF status (58%).<\/li>\n<li>Most respondents (95%) cite the need to improve the use of CTMS in clinical operations. Top drivers<br \/>\nare improved reporting (68%), increased visibility (60%), and more proactive risk mitigation (58%).<\/li>\n<\/ul>\n<h2>The State of Unifying Clinical Systems, Processes, and Stakeholder Collaboration<\/h2>\n<p>\nThe life sciences industry is experiencing rapid innovation and bringing novel drugs to market at<br \/>\nan accelerated pace. In 2018, the industry achieved a record-setting number of 59 drug approvals,<br \/>\ncompared with 46 approvals in 2017, and 22 in 2016.<sup>1<\/sup> As the speed of breakthrough drugs and<br \/>\ntreatments continues to accelerate, organizations will have a greater need for improved trial efficiency<br \/>\nand visibility.<sup>2<\/sup>\n<\/p>\n<p>\nOver the past several years, sponsors and CROs have steadily adopted function-specific technologies<br \/>\nto improve study execution. Highest is EDC, used by 88% of CROs and sponsors surveyed. More than<br \/>\ntwo-thirds (69%) have eTMF applications, up from 57% in 2017. RTSM applications (63%) increased<br \/>\n21-percentage points, likely due to rising protocol design complexity.<sup>3<\/sup>\n<\/p>\n<p>\nMajorities also use CTMS (61%) and safety applications (53%). Nearly one-quarter (23%) have now<br \/>\nadopted newer, purpose-built study start-up applications.\n<\/p>\n<h3>Applications Used to Manage Clinical Studies<\/h3>\n<div class=\"captions\">Base: Total respondents, 2019 N=461, 2017 N=300<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nDoes your organization utilize applications developed by third-party vendors in managing clinical studies? If yes, please indicate which<br \/>\nare currently in use? (Q3)\n<\/div>\n<h2>Drivers and Barriers to Unifying Clinical Systems and Processes<\/h2>\n<p>\nNearly all (97%) respondents say they have at least one major challenge with their clinical applications,<br \/>\nand more than three-quarters (83%) have two or more challenges.\n<\/p>\n<p>\nThe top two issues \u2013 integrating multiple applications (68%) and reporting across multiple applications<br \/>\n(57%) \u2013 are the direct result of clinical application silos.\n<\/p>\n<h3>Biggest Challenges with Clinical Applications<\/h3>\n<div class=\"captions\">Base: Total respondents, N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey2.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat are the biggest challenges, if any, your organization faces in utilizing the clinical applications identified in question 3?<br \/>\n(e.g., CTMS, EDC, eTMF, etc.) Select all that apply. (Q.4)\n<\/div>\n<p>\nWith the focus to improve clinical operations, nearly all respondents (99%) say they need to unify their<br \/>\nclinical trial systems and processes. For more than half, the need to unify is driven by better visibility<br \/>\n(70%), faster study execution (63%), easier collaboration (61%), and improved study quality (56%).\n<\/p>\n<h3>Top Drivers for Unified Clinical Applications<\/h3>\n<div class=\"captions\">Base: Total respondents, N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey3.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nTo the degree your organization needs to better integrate\/unify the clinical applications identified in question 3 (e.g., CTMS, EDC,<br \/>\neTMF, etc.), what are the most important drivers? Select all that apply. (Q.5)\n<\/div>\n<h2>Information Exchange in Clinical Trials<\/h2>\n<p>\nAs sponsors increasingly contract the specialized services of multiple CROs in a single study,<br \/>\ninformation sharing is difficult because of the many different processes and systems used across<br \/>\nstakeholders.<sup>4<\/sup>\n<\/p>\n<p>\nAll respondents (100%) report the need to simplify information exchange with study partners.<br \/>\nThe primary drivers are reducing manual processes (71%), improving collaboration (66%), and<br \/>\nincreasing visibility and oversight (64%).\n<\/p>\n<h3>Top Drivers to Streamline Information Exchange<\/h3>\n<div class=\"captions\">Base: Total respondents, N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey4.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nTo the extent your organization needs to streamline\/simplify information exchange with study partners, what are the primary drivers?<br \/>\nSelect all that apply. (Q8)\n<\/div>\n<p>\nRespondents use a variety of tools to exchange trial data and documents with study partners.<br \/>\nOn average, sponsors and CROs use three methods for information exchange, and one-quarter (25%)<br \/>\nuse at least four methods.\n<\/p>\n<p>\nEmail is the predominant way sponsors exchange information with CROs (78%), followed by portals<br \/>\n(51%), file share (51%), and eTMF applications (38%).\n<\/p>\n<p>\nLess than one-third of sponsors rely on ECM applications (29%) or paper shipments (25%) to<br \/>\nexchange trial information with CROs.\n<\/p>\n<h3>Methods Used by Sponsors to Exchange Information with CROs<\/h3>\n<div class=\"captions\">Base: Sponsor respondents, N=346<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey5.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat methods does your organization use to exchange trial data and documents with study partners? Select all that apply per row. (Q6)\n<\/div>\n<p>\nSponsors and CROs utilize different methods to exchange information with sites, adding further<br \/>\ncomplexity in data sharing and collaboration.\n<\/p>\n<p>\nHalf of CROs (50%) and one-third of sponsors (35%) use paper shipments to manage information<br \/>\nexchange with sites, followed by portals (44% versus 41%, respectively), and eTMF (39% versus 27%,<br \/>\nrespectively).\n<\/p>\n<h3>Methods Used by Sponsors and CROs to Exchange Information with Sites<\/h3>\n<div class=\"captions\">Base: Total respondents, N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey6.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat methods does your organization use to exchange trial data and documents with study partners? Select all that apply per row. (Q6)\n<\/div>\n<p>\nThe majority (96%) of respondents say they have significant challenges with the methods used to<br \/>\nexchange information during clinical trials.\n<\/p>\n<p>\nCollecting data in different systems increases manual effort, causes duplicate data entry, and limits<br \/>\nvisibility. These difficulties can contribute to issues respondents have with tracking and reporting<br \/>\n(71%), misfiled or missing documents (57%), and manual document exchange (47%).\n<\/p>\n<p>\nCROs are more likely to report challenges with misfiled documents (59%) and redundant data<br \/>\ntranscription (43%) than sponsors (54% and 33%, respectively). The higher use of paper and email to<br \/>\nexchange trial documents with sites could contribute to these differences.\n<\/p>\n<p>\nSponsors report more challenges complying with standards (29%) than CROs (18%) perhaps, in part,<br \/>\ndue to sponsor responsibility for adherence to good clinical practice guidelines (GCP) required by<br \/>\nICH E6 (R2).<sup>5<\/sup>\n<\/p>\n<h3>Biggest Challenges with Information Exchange<\/h3>\n<div class=\"captions\">Base: Total respondents, N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey7.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat are the biggest challenges, if any, your organization faces in utilizing the methods of information exchange identified in Q6?<br \/>\nSelect all that apply. (Q7)\n<\/div>\n<h2>Accelerating Study Start-up<\/h2>\n<p>\nThe resource intensive study start-up phase of clinical trials is no faster today than a decade ago.<sup>6<\/sup><br \/>\nMost trials (86%) experience delays in meeting start-up timelines, costing sponsors up to $2M<br \/>\nper month.<sup>7<\/sup>\n<\/p>\n<p>\nTufts Center for the Study of Drug Development (CSDD) research shows that cycle times can be<br \/>\nsignificantly delayed due to paper-based processes and multiple handoffs.<sup>8<\/sup> Consistent with these<br \/>\nfindings, all survey respondents (100%) report challenges with the study start-up process.\n<\/p>\n<p>\nSite contracting and budgeting accounts for most of the cycle time and takes twice as long today<br \/>\nthan five years ago.<sup>9<\/sup> Roughly three-quarters of sponsors and CROs (73%) say site contracting and<br \/>\nbudgeting are their most challenging study start-up processes, up 20-percentage points since 2018.\n<\/p>\n<p>\nHalf (49%) say site identification and selection is a top challenge limiting their ability to speed trials,<br \/>\nfollowed by IRB\/ethics committee approval and planning (42%).\n<\/p>\n<h3>Biggest Challenges with Study Start-up Processes<\/h3>\n<div class=\"captions\">Base: Respondents using a study start-up application, 2019 N=107, 2018 N=85<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey8.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat are the most challenging study start-up processes, if any, that limit your organization\u2019s ability to speed clinical trials?<br \/>\nSelect all that apply. (Q.15)\n<\/div>\n<p>\nFor most, faster study start-up times (71%), streamlined site contracting and budgeting (60%), and<br \/>\nbetter site feasibility and selection outcomes (52%) are the primary drivers to improve study start-up.\n<\/p>\n<p>\nHalf (50%) say easier collaboration between sponsors, CROs, and sites is essential to improve study<br \/>\nstart-up, highlighting the importance of collaboration in driving greater speed and efficiency.\n<\/p>\n<h3>Top Drivers to Improve Study Start-up Processes<\/h3>\n<div class=\"captions\">Base: Respondents using a study start-up application, N=107<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey9.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nTo the extent that your organization needs to improve study start-up processes, what are the primary drivers?<br \/>\nSelect all that apply. (Q.16)\n<\/div>\n<p>\nMost (81%) use spreadsheets to manage study start-up. Roughly one-third or less use CTMS (38%),<br \/>\neTMF (35%), internally developed applications (29%), or online survey tools (25%).\n<\/p>\n<p>\nSignificantly more CROs than sponsors utilize newer, purpose-built study start-up applications (28%<br \/>\nversus 12%, respectively). This may be due, in part, to the increase in outsourcing of study start-up<br \/>\nactivities to CROs.\n<\/p>\n<h3>Tools Used to Manage Study Start-up Processes<\/h3>\n<div class=\"captions\">Base: Total respondents, N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey10.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat tools do you use to manage study start-up processes? Select all that apply. (Q.14)\n<\/div>\n<h2>Active TMF Management and Oversight<\/h2>\n<p>\nOver the past five years, sponsors and CROs have made significant progress modernizing trial<br \/>\nprocesses with the adoption of purpose-built eTMF applications which can help ensure a constant<br \/>\nstate of inspection readiness, increase visibility and oversight, and improve collaboration.<sup>10<\/sup>\n<\/p>\n<p>\nThe number of respondents using an eTMF application has tripled since 2014. More than half of<br \/>\nsponsors and CROs (56%) now use a purpose-built eTMF application, versus 17% in 2014.\n<\/p>\n<h3>eTMF Application Use 2014-2019<\/h3>\n<div class=\"captions\">Base: Total respondents, 2019 N=461, 2018 N=291, 2017 N=253, 2016 N=180, 2015 N=186, 2014 N=161<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey11.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat type of TMF solution do you currently use? Select only one. (Q.11)\n<\/div>\n<p>\nThe increase in the use of eTMF applications is matched by a sharp decline in the use of content<br \/>\nmanagement systems, signaling a shift away from general-purpose methods to manage TMF processes.<br \/>\nToday, only 8% use content management systems for TMF management, versus 31% in 2017.\n<\/p>\n<h3>TMF System Used<\/h3>\n<div class=\"captions\">Base: Total respondents, N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey12.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat type of TMF solution do you currently use? Select only one. (Q.11)\n<\/div>\n<p>\nFindings indicate the move from TMFs which act as static repositories to store and archive documents<br \/>\nupon completion, to modern purpose-built eTMF applications is enabling more \u2018active\u2019 trial<br \/>\nmanagement. Likely because these newer applications automate processes and manage documents<br \/>\nas they are created and reviewed, ensuring the TMF is maintained in a constant state of inspection<br \/>\nreadiness.\n<\/p>\n<p>\nThose using purpose-built eTMF applications report a significant, positive impact on inspectionreadiness<br \/>\n(60%), increased visibility into TMF status (58%), and centralized auditing (36%). They also<br \/>\nreport fewer challenges complying with standards (8% for purpose-built TMF users versus 31% using<br \/>\nother methods) and TMF tracking and reporting (47% versus 64%, respectively).\n<\/p>\n<h3>Benefits of a TMF by Type of TMF<\/h3>\n<div class=\"captions\">Base: Total respondents, N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey13.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat benefits has your organization achieved with the TMF solution specified in Q11? Select all that apply. (Q.13)\n<\/div>\n<h2>Improving Clinical Trial Performance<\/h2>\n<p>\nCTMS applications enable a centralized view of study progress, requiring interoperability with other<br \/>\nclinical systems to support timely decision making, oversight, and streamlined communication among<br \/>\nstakeholders.<sup>11<\/sup>\n<\/p>\n<p>\nNearly all sponsors and CROs surveyed (90%) say they have at least one major challenge with<br \/>\ntheir CTMS application that limits operational efficiency, and three-quarters (74%) have two or more<br \/>\nchallenges. A number of respondents noted multiple, compounding issues:\n<\/p>\n<p>\n<em>\u201cOur CTMS system has a poor user experience, technical malfunctions, slow response times,<br \/>\nis difficult to integrate to multiple data sources, and lacks feasibility reports and tracking.\u201d<\/em>\n<\/p>\n<p>\nIntegrating CTMS applications with other clinical systems (63%) and study performance metrics and<br \/>\nreporting (53%) are the challenges most frequently cited.\n<\/p>\n<p>\nOne-third say CTMS application issues limit efficiency of key trial processes, including monitoring<br \/>\n(38%), resource management (36%), and issue and task management (31%).\n<\/p>\n<p>\nPoorly integrated CTMS systems also prevent stakeholders from getting a complete view of study<br \/>\nprogress and contribute to the difficulty with governance and oversight (29%).\n<\/p>\n<h3>Biggest Challenges with CTMS Applications<\/h3>\n<div class=\"captions\">Base: Respondents using a CTMS application, N=282<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey14.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nWhat challenges, if any, do you have with your organization\u2019s CTMS application that limit your ability to improve clinical operations?<br \/>\nSelect all that apply. (Q.9)\n<\/div>\n<p>\nLikely due to the significance and prevalence of challenges, nearly all (95%) say they need to improve<br \/>\nthe use of CTMS in trial operations. Better analytics and reporting (68%), increased visibility (60%),<br \/>\nand proactive risk identification and mitigation (58%) are among the top reasons to improve.\n<\/p>\n<p>\nEasier internal and external collaboration is also a top driver for roughly half of sponsors and CROs<br \/>\n(48%), underscoring the importance of streamlining communication and information sharing during<br \/>\nstudy execution.\n<\/p>\n<h3>Top Drivers to Improve Clinical Trial Performance<\/h3>\n<div class=\"captions\">Base: Respondents using a CTMS system, N=282<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey15.png\" alt=\"\" \/><\/p>\n<div class=\"captions\">\nTo the degree your organization needs to improve the use of CTMS in clinical trial operations, what are the most important drivers?<br \/>\nSelect all that apply. (Q10)\n<\/div>\n<h2>Conclusion<\/h2>\n<p>\nThis research shows that unifying clinical operations and aligning stakeholders remains an important<br \/>\npriority for sponsors and CROs. While there is work to do, the industry has made progress in moving<br \/>\ntoward a unified clinical operating model which is having a significant, measurable impact in:\n<\/p>\n<ul>\n<li><strong>Speeding study start-up:<\/strong> Study start-up has emerged as a major area of focus for sponsors and<br \/>\nCROs alike. With it, the adoption of study start-up applications is on the rise and is reducing cycle<br \/>\ntimes by eliminating manual processes and streamlining stakeholder communication \u2013 bringing a<br \/>\nhigher level of predictability, quality, and speed to clinical trials.<\/li>\n<li><strong>Increasing study quality and compliance:<\/strong> Positive change is underway as the industry unifies<br \/>\nand modernizes its TMF processes for active TMF management and oversight. As documents are<br \/>\nmanaged in real-time as the TMF is generated, a constant state of inspection-readiness is achieved,<br \/>\nleading to significant gains in compliance, visibility, and process improvements that streamline the<br \/>\nentire study process.<\/li>\n<li><strong>Eliminating silos:<\/strong> There is tremendous opportunity to reduce system and process fragmentation that<br \/>\nlimit trial performance and slow execution. Modern clinical trial management systems on a unified<br \/>\nplatform eliminate silos, improve study visibility, and enable centralized monitoring and oversight<br \/>\nneeded to effectively manage and optimize trials.<\/li>\n<li><strong>Streamlining information exchange and collaboration:<\/strong> The ability to exchange information easily is<br \/>\none of the greatest areas of opportunity for improving how sponsors, CROs, and sites work together in<br \/>\nclinical trials. Unified processes and systems streamline stakeholder communication and collaboration.<br \/>\nThe exchange of trial information is simplified (and where possible, automated), and study progress is<br \/>\nmade visible to all parties in real-time, ensuring stakeholder alignment and improved trial performance.<\/li>\n<\/ul>\n<p>\nThere is universal recognition that a unified clinical environment is essential to transforming clinical<br \/>\noperations \u2013 and the industry has made steady progress toward that goal. The resulting gains in<br \/>\nefficiency, visibility, and quality will enable the industry to rethink how studies are conducted \u2013 and<br \/>\nadopt new and more effective business models that drive trial performance, simplify data sharing and<br \/>\ncollaboration, and ultimately, accelerate delivery of breakthrough drugs and treatments to market.\n<\/p>\n<h2>Survey Methods<\/h2>\n<p>\nThe survey consisted of 16 questions, many of which included sub-questions with response matrices.<br \/>\nSurvey questions were designed for individuals with knowledge of clinical operations processes<br \/>\nand with partial or full responsibility for clinical operations within their organization. The survey was<br \/>\ncommissioned by Veeva Systems and conducted by Fierce Markets, Applied Clinical Trials, and Veeva<br \/>\nSystems. Completion of the survey was voluntary. Respondents received a $5 or $10 Amazon gift card<br \/>\nand were offered a summary of survey results. No other compensation was offered or provided.\n<\/p>\n<h2>Survey Respondents<\/h2>\n<p>\nOf the approximately 270,020 individuals invited to take the survey, a total of 2,484 surveys were<br \/>\ninitiated, the majority of which were terminated based on a qualification question gauging the level<br \/>\nof responsibility for clinical in their organization. More than 830 unverified responses were eliminated,<br \/>\nyielding 461 qualified responses.\n<\/p>\n<h3>Survey Respondent Demographics<\/h3>\n<div class=\"captions\">Base: Total respondents N=461<\/div>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2021\/12\/Clinical-Operations-Survey16.png\" alt=\"\" \/><\/p>\n<p><footnotes><\/p>\n<p><sup>1<\/sup> U.S. Food &#038; Drug Administration. 2018 New Drug Therapy Approvals.<br \/>\n<sup>2<\/sup> U.S Food &#038; Drug Administration. FDA Statement on New Strategies to Modernize Clinical Trials. March 2019.<br \/>\n<sup>3<\/sup> Getz KA, Campo RA. New benchmarks characterizing growth in protocol design complexity. Therapeutic Innovation &#038; Regulatory Science. 2017.<br \/>\n<sup>4<\/sup> DIA Global Forum. The Next Big Step Toward a Collaborative Clinical Ecosystem. October 2018.<br \/>\n<sup>5<\/sup> Integrated Addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2) 2016.<br \/>\n<sup>6<\/sup> Lamberti, MJ, Chakravarthy, R, Getz, KA. Assessing Practices &#038; Inefficiencies with Site Selection, Study Start-Up, and Site Activation. Applied Clinical Trials, August 2016.<br \/>\n<sup>7<\/sup> NCBI. Brianna M Krafcik, Gheorghe Doros, Mariana A Malikova. A single center analysis of factors influencing study start-up timelines in clinical trials. July 2017.<br \/>\n<sup>8<\/sup> Applied Clinical Trials. The Need and Opportunity for a New Paradigm in Clinical Trial Execution. June 2018.<br \/>\n<sup>9<\/sup> BioSpace. Site Contracts from Weeks to Months: Results from KMR Group\u2019s Site Contracts Study. August 2016.<br \/>\n<sup>10<\/sup> Veeva 2018 Unified Clinical Operations Survey. Top drivers to optimize TMF processes. (Q13).<br \/>\n<sup>11<\/sup> First Analysis Securities Corporation. eClinical Solutions: Streamlining the introduction of new drugs and medical technology. January 2018.<br \/>\n<\/footnotes><\/p>\n<hr>\n<p>Find out more about Vault Clinical Suite <a href=\"\/eu\/products\/vault-clinical\/\">here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>See new results from one of the industry&#8217;s largest, global clinical operations surveys.<\/p>\n","protected":false},"featured_media":23996,"parent":0,"template":"","class_list":["post-23898","resources","type-resources","status-publish","has-post-thumbnail","hentry","search-do-not-search","resource-html-content-yes","resource-area-20-clinical-operations","resource-area-20-vault-platform-area","resource-product-20-ctms","resource-product-20-etmf","resource-product-20-payments","resource-product-20-vault-platform","resource-type-report"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 5.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"See new results from one of the industry&#039;s largest, global clinical operations surveys.\" \/>\n\t<meta name=\"robots\" content=\"noindex, nofollow, noarchive, noimageindex, max-snippet:-1, max-video-preview:-1\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 5.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Veeva Systems Europe\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Veeva 2019 Unified Clinical Operations Survey Report | Veeva Systems Europe\" \/>\n\t\t<meta property=\"og:description\" content=\"See new results from one of the industry&#039;s largest, global clinical operations surveys.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2026\/08\/web-default-featured-image-1200x630-2@2x.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2026\/08\/web-default-featured-image-1200x630-2@2x.jpg\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2019-10-01T10:30:41+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-09-04T14:10:34+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Veeva 2019 Unified Clinical Operations Survey Report | Veeva Systems Europe\" \/>\n\t\t<meta name=\"twitter:description\" content=\"See new results from one of the industry&#039;s largest, global clinical operations surveys.\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2026\/08\/web-default-featured-image-1200x630-2@2x.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/veeva-2019-unified-clinical-operations-survey-report\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.veeva.com\\\/eu\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/#listItem\",\"name\":\"Resources\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/#listItem\",\"position\":2,\"name\":\"Resources\",\"item\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/search\\\/do-not-search\\\/#listItem\",\"name\":\"Do Not Search\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/search\\\/do-not-search\\\/#listItem\",\"position\":3,\"name\":\"Do Not Search\",\"item\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/search\\\/do-not-search\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/veeva-2019-unified-clinical-operations-survey-report\\\/#listItem\",\"name\":\"Veeva 2019 Unified Clinical Operations Survey Report\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/#listItem\",\"name\":\"Resources\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/veeva-2019-unified-clinical-operations-survey-report\\\/#listItem\",\"position\":4,\"name\":\"Veeva 2019 Unified Clinical Operations Survey Report\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/search\\\/do-not-search\\\/#listItem\",\"name\":\"Do Not Search\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/#organization\",\"name\":\"Veeva Systems Europe\",\"description\":\"EU Site\",\"url\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/veeva-2019-unified-clinical-operations-survey-report\\\/#webpage\",\"url\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/veeva-2019-unified-clinical-operations-survey-report\\\/\",\"name\":\"Veeva 2019 Unified Clinical Operations Survey Report | Veeva Systems Europe\",\"description\":\"See new results from one of the industry's largest, global clinical operations surveys.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/veeva-2019-unified-clinical-operations-survey-report\\\/#breadcrumblist\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/Top-3-Challenges-of-Legacy-Clinical-Trial-Management-Systems-.png\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/veeva-2019-unified-clinical-operations-survey-report\\\/#mainImage\",\"width\":340,\"height\":240},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/resources\\\/veeva-2019-unified-clinical-operations-survey-report\\\/#mainImage\"},\"datePublished\":\"2019-10-01T12:30:41+02:00\",\"dateModified\":\"2026-09-04T16:10:34+02:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/#website\",\"url\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/\",\"name\":\"Veeva Systems Europe\",\"description\":\"EU Site\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.veeva.com\\\/eu\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>Veeva 2019 Unified Clinical Operations Survey Report | Veeva Systems Europe<\/title>\n\n","aioseo_head_json":{"title":"Veeva 2019 Unified Clinical Operations Survey Report | Veeva Systems Europe","description":"See new results from one of the industry's largest, global clinical operations surveys.","canonical_url":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/","robots":"noindex, nofollow, noarchive, noimageindex, max-snippet:-1, max-video-preview:-1","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu#listItem","position":1,"name":"Home","item":"https:\/\/www.veeva.com\/eu","nextItem":{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu\/resources\/#listItem","name":"Resources"}},{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu\/resources\/#listItem","position":2,"name":"Resources","item":"https:\/\/www.veeva.com\/eu\/resources\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu\/search\/do-not-search\/#listItem","name":"Do Not Search"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu\/search\/do-not-search\/#listItem","position":3,"name":"Do Not Search","item":"https:\/\/www.veeva.com\/eu\/search\/do-not-search\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/#listItem","name":"Veeva 2019 Unified Clinical Operations Survey Report"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu\/resources\/#listItem","name":"Resources"}},{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/#listItem","position":4,"name":"Veeva 2019 Unified Clinical Operations Survey Report","previousItem":{"@type":"ListItem","@id":"https:\/\/www.veeva.com\/eu\/search\/do-not-search\/#listItem","name":"Do Not Search"}}]},{"@type":"Organization","@id":"https:\/\/www.veeva.com\/eu\/#organization","name":"Veeva Systems Europe","description":"EU Site","url":"https:\/\/www.veeva.com\/eu\/"},{"@type":"WebPage","@id":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/#webpage","url":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/","name":"Veeva 2019 Unified Clinical Operations Survey Report | Veeva Systems Europe","description":"See new results from one of the industry's largest, global clinical operations surveys.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/www.veeva.com\/eu\/#website"},"breadcrumb":{"@id":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/#breadcrumblist"},"image":{"@type":"ImageObject","url":"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2019\/06\/Top-3-Challenges-of-Legacy-Clinical-Trial-Management-Systems-.png","@id":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/#mainImage","width":340,"height":240},"primaryImageOfPage":{"@id":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/#mainImage"},"datePublished":"2019-10-01T12:30:41+02:00","dateModified":"2026-09-04T16:10:34+02:00"},{"@type":"WebSite","@id":"https:\/\/www.veeva.com\/eu\/#website","url":"https:\/\/www.veeva.com\/eu\/","name":"Veeva Systems Europe","description":"EU Site","inLanguage":"en-US","publisher":{"@id":"https:\/\/www.veeva.com\/eu\/#organization"}}]},"og:locale":"en_US","og:site_name":"Veeva Systems Europe","og:type":"article","og:title":"Veeva 2019 Unified Clinical Operations Survey Report | Veeva Systems Europe","og:description":"See new results from one of the industry's largest, global clinical operations surveys.","og:url":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/","og:image":"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2026\/08\/web-default-featured-image-1200x630-2@2x.jpg","og:image:secure_url":"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2026\/08\/web-default-featured-image-1200x630-2@2x.jpg","article:published_time":"2019-10-01T10:30:41+00:00","article:modified_time":"2026-09-04T14:10:34+00:00","twitter:card":"summary","twitter:title":"Veeva 2019 Unified Clinical Operations Survey Report | Veeva Systems Europe","twitter:description":"See new results from one of the industry's largest, global clinical operations surveys.","twitter:image":"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2026\/08\/web-default-featured-image-1200x630-2@2x.jpg"},"aioseo_meta_data":{"post_id":"23898","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"article","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"summary","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":"{\"article\":{\"articleType\":\"BlogPosting\"},\"course\":{\"name\":\"\",\"description\":\"\",\"provider\":\"\"},\"faq\":{\"pages\":[]},\"product\":{\"reviews\":[]},\"recipe\":{\"ingredients\":[],\"instructions\":[],\"keywords\":[]},\"software\":{\"reviews\":[],\"operatingSystems\":[]},\"webPage\":{\"webPageType\":\"WebPage\"}}","pillar_content":false,"robots_default":false,"robots_noindex":true,"robots_noarchive":true,"robots_nosnippet":false,"robots_nofollow":true,"robots_noimageindex":true,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"limit_modified_date":false,"open_ai":"{\"title\":{\"suggestions\":[],\"usage\":0},\"description\":{\"suggestions\":[],\"usage\":0}}","created":"2021-08-24 17:49:10","updated":"2026-09-04 15:10:53","focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"breadcrumb_settings":null,"seo_analyzer_scan_date":"2026-09-04 15:10:53"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.veeva.com\/eu\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.veeva.com\/eu\/resources\/\" title=\"Resources\">Resources<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.veeva.com\/eu\/search\/do-not-search\/\" title=\"Do Not Search\">Do Not Search<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\tVeeva 2019 Unified Clinical Operations Survey Report\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.veeva.com\/eu"},{"label":"Resources","link":"https:\/\/www.veeva.com\/eu\/resources\/"},{"label":"Do Not Search","link":"https:\/\/www.veeva.com\/eu\/search\/do-not-search\/"},{"label":"Veeva 2019 Unified Clinical Operations Survey Report","link":"https:\/\/www.veeva.com\/eu\/resources\/veeva-2019-unified-clinical-operations-survey-report\/"}],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/23898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":3,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/23898\/revisions"}],"predecessor-version":[{"id":101684,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/23898\/revisions\/101684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/23996"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=23898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}